Dkc Fokus-5 Lzip OOD
- Address
- lock Available on a paid plan
DKC Fokus-5 LZIP OOD - Autoimmune and Inflammatory Disease Research
DKC Fokus-5 LZIP OOD is a specialized clinical research center with extensive expertise in autoimmune and inflammatory conditions. The center demonstrates particular strength in investigating novel therapeutic approaches for complex rheumatologic disorders and dermatologic inflammatory diseases, with a comprehensive portfolio spanning both rare and common autoimmune conditions.
- Systemic Lupus Erythematosus (SLE) and cutaneous lupus erythematosus, evaluating multiple JAK inhibitors and biologics
- Hidradenitis Suppurativa treatment studies with advanced immunomodulatory agents
- Rheumatoid Arthritis and Psoriatic Arthritis, including biosimilar development and TNF-inhibitor studies
- Inflammatory Myopathies (dermatomyositis and polymyositis) and axial spondyloarthritis
The research center has developed significant capabilities in evaluating JAK pathway inhibitors, including upadacitinib, filgotinib, and deucravacitinib, across multiple indications. Additional focus areas include rare inflammatory conditions such as alopecia areata and atopic dermatitis, as well as metabolic disorders like gout with hyperuricemia. The center's participation in Phase 2 through Phase 4 trials, including long-term extension studies, demonstrates its commitment to comprehensive evaluation of both efficacy and safety profiles throughout the full spectrum of drug development.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 8 therapeutic areas and 15 of 57 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 56 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 13 by active trials.
- 1Pfizer Inc.3active
lock +12 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AbbVie Deutschland GmbH & Co. KG7trials
lock +14 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 476 other sites in Bulgaria
Therapeutic Area Benchmark — Bulgaria
Select a therapeutic area to compare against other sites in Bulgaria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Bulgaria
Market Share
Country: Bulgaria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Dkc Fokus-5 Lzip OOD
lock Showing 1 of 56 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| 22104: A Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2b/3 Study to Evaluate the Efficacy and Safety of Izokibep in Subjects with Active Psoriatic Arthritis | Acelyrin Inc. | Phase IV | Not Recruiting | Apr 2023 | Oct 2024 |
IMP list
lock Showing 1 of 57 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Upadacitinib | 6 | Unknown | 2016-05-10 | 2024-06-17 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.